ORPHA:420259
Secondary pulmonary alveolar proteinosis
Also known as: Secondary PAP
Publications
490
85.1th percentile
Trials
0
Interventional, condition-specific
Researchers
1,205
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare, acquired, interstitial lung disease, characterized by alveolar surfactant accumulation, cough, dyspnea and respiratory insufficiency. The disease may be secondary to hematological disorder, toxic inhalation, and infection or may occur within the setting of immunosuppression after transplantation.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018483
- UMLS:C3873302
Additional Mondo synonyms (2)
SPAP · secondary PAP
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
490 matched papers (304 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 22 for broader category pulmonary alveolar proteinosis
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
490
490 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
490 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
304 in the last 10 years · medium confidence · 85.1th percentile (publications denominator)
Phrase hits: 490 · MeSH hits: 0
Who's working on it?
1,205
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Nakata K12 papers · 2026
Bioscience Medical Research Center, Niigata University, 1-754 Asahimachi Dori, Chuoku, Niigata 951-8520, Japan. Electronic address: radical@med.niigata-u.ac.jp.
Papers in Europe PMC - 02Ishii H8 papers · 2020
Department of Respiratory Medicine, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, 181-8611, Japan. Electronic address: h141@ks.kyorin-u.ac.jp.
Papers in Europe PMC - 03McCarthy C6 papers · 2026
Department of Respiratory Medicine, St. Vincent's University Hospital, Dublin, Ireland.
Papers in Europe PMC - 04Bonella F5 papers · 2026
Center for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik University Hospital, University of Duisburg-Essen, Essen, Germany.
Papers in Europe PMC - 05Chen J5 papers · 2025
Department of Thoracic Surgery, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, China. Electronic address: chenjy@wuxiph.com.
Papers in Europe PMC - 06Inoue Y5 papers · 2024
Department of Diffuse Lung Diseases and Respiratory Failure, Clinical Research Center, NHO Kinki-Chuo Chest Medical Center, Osaka, Japan.
Papers in Europe PMC - 07Takada T5 papers · 2020
Division of Respiratory Medicine, Niigata University Graduate School of Medical and Dental Sciences, 1-754 Asahimachi-dori, Chuo-ku, Niigata 951-8520, Japan. Electronic address: ttakada@med.niigata-u.ac.jp.
Papers in Europe PMC - 08Zhang J5 papers · 2024
Guanganmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Papers in Europe PMC - 09Chen Y4 papers · 2026
Department of Thoracic Surgery, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, China.
Papers in Europe PMC - 10Ichiwata T4 papers · 2014
Department of Respiratory Medicine, Dokkyo University Hospital, Saitama, Japan.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 22 trials are registered for pulmonary alveolar proteinosis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
medium confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
22 interventional trials matched pulmonary alveolar proteinosis, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: pulmonary alveolar proteinosis
22
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05761899·RECRUITING·Safety and Efficacy of PMT Therapy of hPAP
Conditions: Hereditary Pulmonary Alveolar Proteinosis·Matched via name phrase
- NCT06431776·RECRUITING·Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
Conditions: Autoimmune Pulmonary Alveolar Proteinosis·Matched via name phrase
- NCT06989333·NOT YET RECRUITING·Local Spraying of GM-CSF Via Bronchoscopy in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis
Conditions: Pulmonary Alveolar Proteinosis·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Secondary pulmonary alveolar proteinosis" OR "Secondary PAP"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Secondary pulmonary alveolar proteinosis" OR "Secondary PAP"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"pulmonary alveolar proteinosis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: SPAP
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T15:46:32.154Z
